OBJECTIVE: Recanalization of arterial obstruction is associated with improved clinical outcomes. There are no controlled data demonstrating whether arterial obstruction status predicts the treatment effect of intravenous (IV) tissue plasminogen activator (tPA). We aimed to determine if the presence of arterial obstruction improves the treatment effect of IV tPA over placebo in attenuating infarct growth. METHODS: We analyzed 175 ischemic stroke patients treated in the 3-6 hour time window from the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) trial (randomized toIV tPA or placebo) and Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE) study (all treated with IV tPA). Infarct growth was calculated as the difference between baseline diffusion-weighted imaging (DWI) and final T2 lesion volumes. Baseline arterial obstruction of large intracranial arteries was graded on magnetic resonance angiography (MRA). RESULTS: Among the 116 patients with adequate baseline MRA and final lesion assessment, 72 had arterial obstruction (48 tPA, 24 placebo) and 44 no arterial obstruction (33 tPA, 11 placebo). Infarct growth was lower in the tPA than placebo group (median difference 26ml, 95% confidence interval [CI], 1-50) in patients with arterial obstruction, but was similar in patients with no arterial obstruction (median difference 5ml, 95%CI, -3 to 9). Infarct growth attenuation with tPA over placebo treatment was greater among patients with arterial obstruction than those without arterial obstruction by a median of 32ml (95%CI, 21-43, p < 0.001). INTERPRETATION: The treatment effect of IV tPA over placebo was greater with baseline arterial obstruction, supporting arterial obstruction status as a consideration in selecting patients more likely to benefit from IV thrombolysis.
RCT Entities:
OBJECTIVE: Recanalization of arterial obstruction is associated with improved clinical outcomes. There are no controlled data demonstrating whether arterial obstruction status predicts the treatment effect of intravenous (IV) tissue plasminogen activator (tPA). We aimed to determine if the presence of arterial obstruction improves the treatment effect of IV tPA over placebo in attenuating infarct growth. METHODS: We analyzed 175 ischemic strokepatients treated in the 3-6 hour time window from the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) trial (randomized to IV tPA or placebo) and Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE) study (all treated with IV tPA). Infarct growth was calculated as the difference between baseline diffusion-weighted imaging (DWI) and final T2 lesion volumes. Baseline arterial obstruction of large intracranial arteries was graded on magnetic resonance angiography (MRA). RESULTS: Among the 116 patients with adequate baseline MRA and final lesion assessment, 72 had arterial obstruction (48 tPA, 24 placebo) and 44 no arterial obstruction (33 tPA, 11 placebo). Infarct growth was lower in the tPA than placebo group (median difference 26ml, 95% confidence interval [CI], 1-50) in patients with arterial obstruction, but was similar in patients with no arterial obstruction (median difference 5ml, 95%CI, -3 to 9). Infarct growth attenuation with tPA over placebo treatment was greater among patients with arterial obstruction than those without arterial obstruction by a median of 32ml (95%CI, 21-43, p < 0.001). INTERPRETATION: The treatment effect of IV tPA over placebo was greater with baseline arterial obstruction, supporting arterial obstruction status as a consideration in selecting patients more likely to benefit from IV thrombolysis.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: Deidre A De Silva; John N Fink; Soren Christensen; Martin Ebinger; Christopher Bladin; Christopher R Levi; Mark Parsons; Ken Butcher; P Alan Barber; Geoffrey A Donnan; Stephen M Davis Journal: Stroke Date: 2009-05-28 Impact factor: 7.914
Authors: Gregory W Albers; Vincent N Thijs; Lawrence Wechsler; Stephanie Kemp; Gottfried Schlaug; Elaine Skalabrin; Roland Bammer; Wataru Kakuda; Maarten G Lansberg; Ashfaq Shuaib; William Coplin; Scott Hamilton; Michael Moseley; Michael P Marks Journal: Ann Neurol Date: 2006-11 Impact factor: 10.422
Authors: P A Barber; S M Davis; D G Darby; P M Desmond; R P Gerraty; Q Yang; D Jolley; G A Donnan; B M Tress Journal: Neurology Date: 1999-04-12 Impact factor: 9.910
Authors: Jens Fiehler; Karina Knudsen; Götz Thomalla; Einar Goebell; Michael Rosenkranz; Cornelius Weiller; Joachim Röther; Hermann Zeumer; Thomas Kucinski Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: Stephen M Davis; Geoffrey A Donnan; Mark W Parsons; Christopher Levi; Kenneth S Butcher; Andre Peeters; P Alan Barber; Christopher Bladin; Deidre A De Silva; Graham Byrnes; Jonathan B Chalk; John N Fink; Thomas E Kimber; David Schultz; Peter J Hand; Judith Frayne; Graeme Hankey; Keith Muir; Richard Gerraty; Brian M Tress; Patricia M Desmond Journal: Lancet Neurol Date: 2008-02-28 Impact factor: 44.182
Authors: Michael P Marks; Jean-Marc Olivot; Stephanie Kemp; Maarten G Lansberg; Roland Bammer; Lawrence R Wechsler; Gregory W Albers; Vincent Thijs Journal: Radiology Date: 2008-11 Impact factor: 11.105
Authors: J Röther; P D Schellinger; A Gass; M Siebler; A Villringer; J B Fiebach; J Fiehler; O Jansen; T Kucinski; V Schoder; K Szabo; G J Junge-Hülsing; M Hennerici; H Zeumer; K Sartor; C Weiller; W Hacke Journal: Stroke Date: 2002-10 Impact factor: 7.914
Authors: Yawu Liu; Jari O Karonen; Ritva L Vanninen; Juho Nuutinen; Anna Koskela; Seppo Soimakallio; Hannu J Aronen Journal: Radiology Date: 2004-03-24 Impact factor: 11.105
Authors: Louisa von Baumgarten; Kolja M Thierfelder; Sebastian E Beyer; Alena B Baumann; Christine Bollwein; Hendrik Janssen; Maximilian F Reiser; Andreas Straube; Wieland H Sommer Journal: Neuroradiology Date: 2016-01-18 Impact factor: 2.804
Authors: Ana Muñoz-Jurado; Begoña M Escribano; Javier Caballero-Villarraso; Alberto Galván; Eduardo Agüera; Abel Santamaría; Isaac Túnez Journal: Inflammopharmacology Date: 2022-06-05 Impact factor: 5.093